Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4473144
Max Phase: Preclinical
Molecular Formula: C51H77N10O22P
Molecular Weight: 1213.20
Molecule Type: Unknown
Associated Items:
ID: ALA4473144
Max Phase: Preclinical
Molecular Formula: C51H77N10O22P
Molecular Weight: 1213.20
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(C)=O)[C@@H](C)O)C(=O)N[C@@H](Cc1cc(=O)oc2cc(OP(=O)(O)O)ccc12)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(N)=O)C(C)C)C(C)C
Standard InChI: InChI=1S/C51H77N10O22P/c1-11-24(8)41(60-51(78)42(25(9)63)61-47(74)34(20-62)57-45(72)33(19-37(67)68)53-26(10)64)50(77)56-32(15-27-16-38(69)82-35-17-28(12-13-29(27)35)83-84(79,80)81)46(73)58-40(23(6)7)49(76)59-39(22(4)5)48(75)55-31(14-21(2)3)44(71)54-30(43(52)70)18-36(65)66/h12-13,16-17,21-25,30-34,39-42,62-63H,11,14-15,18-20H2,1-10H3,(H2,52,70)(H,53,64)(H,54,71)(H,55,75)(H,56,77)(H,57,72)(H,58,73)(H,59,76)(H,60,78)(H,61,74)(H,65,66)(H,67,68)(H2,79,80,81)/t24-,25+,30-,31-,32-,33-,34-,39-,40-,41-,42-/m0/s1
Standard InChI Key: UYDFVPAEIFUQAZ-JGMOYVOUSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1213.20 | Molecular Weight (Monoisotopic): 1212.4952 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Ma ES, Barrios AM.. (2019) Rational design of a SHP-2 targeted, fluorogenic peptide substrate., 29 (17): [PMID:31351693] [10.1016/j.bmcl.2019.07.034] |
Source(1):